Interferon-γ induced by administration of recombinant interleukin-2 to patients with cancer: Kinetics, dose dependence, and correlation with physiological and therapeutic response

M. W. Konrad, S. K. DeWitt, E. C. Bradley, G. Goodman, E. C. Groves, Evan M Hersh, R. L. Krigel, A. Rudolph

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The administration of recombinant interleukin-2 as an i.v. bolus at dose levels of from 1 to 30 MIU/m2 to patients with cancer induces easily measurable serum interferon-γ levels of 1 to 500 U/ml. After a lag of 1 h, interferon-γ rises to a maximum at 4 h and then slowly decreases. The peak values are poorly correlated with the dose of interleukin-2, and thus must be also be dependent on other factors. Successive administration of interleukin- 2 typically increases the peak level of interferon-γ fourfold, but does not diminish the lag period. Peak levels of interferon-γ are also increased by concurrent administration of interferon-β with interleukin-2. Continuous i.v. infusion of 1.5 to 20 MIU/m2 of interleukin-2/day results in interferon-γ levels of 1 to 7 U/ml. Hypotension, which is characteristically associated with interleukin-2 administration, is correlated with interferon- γ levels in only some patients. There was no apparent correlation between tumor regression and serum interferon-γ levels.

Original languageEnglish (US)
Pages (from-to)55-63
Number of pages9
JournalJournal of Immunotherapy
Volume12
Issue number1
StatePublished - 1992
Externally publishedYes

Fingerprint

Interferons
Interleukin-2
Neoplasms
Therapeutics
Serum
Hypotension

Keywords

  • Cancer
  • Interferon-β
  • Interferon-γ
  • Interleukin-2

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Pharmacology

Cite this

Interferon-γ induced by administration of recombinant interleukin-2 to patients with cancer : Kinetics, dose dependence, and correlation with physiological and therapeutic response. / Konrad, M. W.; DeWitt, S. K.; Bradley, E. C.; Goodman, G.; Groves, E. C.; Hersh, Evan M; Krigel, R. L.; Rudolph, A.

In: Journal of Immunotherapy, Vol. 12, No. 1, 1992, p. 55-63.

Research output: Contribution to journalArticle

Konrad, M. W. ; DeWitt, S. K. ; Bradley, E. C. ; Goodman, G. ; Groves, E. C. ; Hersh, Evan M ; Krigel, R. L. ; Rudolph, A. / Interferon-γ induced by administration of recombinant interleukin-2 to patients with cancer : Kinetics, dose dependence, and correlation with physiological and therapeutic response. In: Journal of Immunotherapy. 1992 ; Vol. 12, No. 1. pp. 55-63.
@article{e66b60657f9f4ad9ab38f01ceed22208,
title = "Interferon-γ induced by administration of recombinant interleukin-2 to patients with cancer: Kinetics, dose dependence, and correlation with physiological and therapeutic response",
abstract = "The administration of recombinant interleukin-2 as an i.v. bolus at dose levels of from 1 to 30 MIU/m2 to patients with cancer induces easily measurable serum interferon-γ levels of 1 to 500 U/ml. After a lag of 1 h, interferon-γ rises to a maximum at 4 h and then slowly decreases. The peak values are poorly correlated with the dose of interleukin-2, and thus must be also be dependent on other factors. Successive administration of interleukin- 2 typically increases the peak level of interferon-γ fourfold, but does not diminish the lag period. Peak levels of interferon-γ are also increased by concurrent administration of interferon-β with interleukin-2. Continuous i.v. infusion of 1.5 to 20 MIU/m2 of interleukin-2/day results in interferon-γ levels of 1 to 7 U/ml. Hypotension, which is characteristically associated with interleukin-2 administration, is correlated with interferon- γ levels in only some patients. There was no apparent correlation between tumor regression and serum interferon-γ levels.",
keywords = "Cancer, Interferon-β, Interferon-γ, Interleukin-2",
author = "Konrad, {M. W.} and DeWitt, {S. K.} and Bradley, {E. C.} and G. Goodman and Groves, {E. C.} and Hersh, {Evan M} and Krigel, {R. L.} and A. Rudolph",
year = "1992",
language = "English (US)",
volume = "12",
pages = "55--63",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Interferon-γ induced by administration of recombinant interleukin-2 to patients with cancer

T2 - Kinetics, dose dependence, and correlation with physiological and therapeutic response

AU - Konrad, M. W.

AU - DeWitt, S. K.

AU - Bradley, E. C.

AU - Goodman, G.

AU - Groves, E. C.

AU - Hersh, Evan M

AU - Krigel, R. L.

AU - Rudolph, A.

PY - 1992

Y1 - 1992

N2 - The administration of recombinant interleukin-2 as an i.v. bolus at dose levels of from 1 to 30 MIU/m2 to patients with cancer induces easily measurable serum interferon-γ levels of 1 to 500 U/ml. After a lag of 1 h, interferon-γ rises to a maximum at 4 h and then slowly decreases. The peak values are poorly correlated with the dose of interleukin-2, and thus must be also be dependent on other factors. Successive administration of interleukin- 2 typically increases the peak level of interferon-γ fourfold, but does not diminish the lag period. Peak levels of interferon-γ are also increased by concurrent administration of interferon-β with interleukin-2. Continuous i.v. infusion of 1.5 to 20 MIU/m2 of interleukin-2/day results in interferon-γ levels of 1 to 7 U/ml. Hypotension, which is characteristically associated with interleukin-2 administration, is correlated with interferon- γ levels in only some patients. There was no apparent correlation between tumor regression and serum interferon-γ levels.

AB - The administration of recombinant interleukin-2 as an i.v. bolus at dose levels of from 1 to 30 MIU/m2 to patients with cancer induces easily measurable serum interferon-γ levels of 1 to 500 U/ml. After a lag of 1 h, interferon-γ rises to a maximum at 4 h and then slowly decreases. The peak values are poorly correlated with the dose of interleukin-2, and thus must be also be dependent on other factors. Successive administration of interleukin- 2 typically increases the peak level of interferon-γ fourfold, but does not diminish the lag period. Peak levels of interferon-γ are also increased by concurrent administration of interferon-β with interleukin-2. Continuous i.v. infusion of 1.5 to 20 MIU/m2 of interleukin-2/day results in interferon-γ levels of 1 to 7 U/ml. Hypotension, which is characteristically associated with interleukin-2 administration, is correlated with interferon- γ levels in only some patients. There was no apparent correlation between tumor regression and serum interferon-γ levels.

KW - Cancer

KW - Interferon-β

KW - Interferon-γ

KW - Interleukin-2

UR - http://www.scopus.com/inward/record.url?scp=0026650474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026650474&partnerID=8YFLogxK

M3 - Article

C2 - 1637783

AN - SCOPUS:0026650474

VL - 12

SP - 55

EP - 63

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 1

ER -